Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1773Uterine Cervical Neoplasms 1499Endometrial Neoplasms 833Breast Neoplasms 434Carcinoma, Ovarian Epithelial 405Fallopian Tube Neoplasms 399Uterine Cervical Dysplasia 276Neoplasms 252Colorectal Neoplasms 179Uterine Neoplasms 173Peritoneal Neoplasms 170Vulvar Neoplasms 155Lung Neoplasms 150Pancreatic Neoplasms 141Prostatic Neoplasms 135Recurrence 128Stomach Neoplasms 126Colonic Neoplasms 116Papillomavirus Infections 115Melanoma 101Sarcoma 97Urinary Bladder Neoplasms 95Vaginal Neoplasms 93Carcinoma, Non-Small-Cell Lung 92Head and Neck Neoplasms 91Neoplasm Metastasis 83Esophageal Neoplasms 82Testicular Neoplasms 80Rectal Neoplasms 71Kidney Neoplasms 62

Interventions

enzalutamide 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrent Endometrial Endometrioid Adenocarcinoma × Gynecologic × Clear all
NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 14 charts
Gynecologic

Recurrent Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡